{
    "clinical_study": {
        "@rank": "82401", 
        "arm_group": [
            {
                "arm_group_label": "Standard arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Induction therapy:\nPatients will receive induction therapy (one or two cycles) with daunorubicin 60 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7. No dose reduction is planned in elderly (>60 years) patients.\nConsolidation therapy:\nPatients  will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.\nFollow-up period:\nThere is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
            }, 
            {
                "arm_group_label": "Investigational arm", 
                "arm_group_type": "Experimental", 
                "description": "Induction therapy:\nPatients will receive induction therapy (one or two cycles) with daunorubicin 60 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7. No dose reduction is planned in elderly (>60 years) patients. Patients will receive dasatinib 100 mg once daily (QD) on days 8-21.\nConsolidation therapy:\nPatients will receive consolidation therapy for 4 cycles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 4-21.\nMaintenance therapy:\nPatients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized phase III open-label, multicenter trial evaluating standard induction\n      therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose\n      cytarabine [HDAC]) with or without dasatinib in adult patients with newly diagnosed CBF-AML;\n      in the investigational arm, consolidation therapy is followed by a one-year maintenance\n      therapy with dasatinib. Patients with molecular disease persistence or molecular relapse as\n      assessed by quantitative RQ-PCR for the CBF fusion transcripts will be eligible for\n      hematopoietic stem cell transplantation before overt hematologic relapse occurs. Primary\n      endpoint is event-free survival.\n\n      AML patients will be assessed for the CBF fusion genes in one of two AMLSG central\n      laboratories within 48 hours of diagnosis, and only patients with CBF-AML will be enrolled."
        }, 
        "brief_title": "Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel\u2122) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)", 
        "completion_date": {
            "#text": "July 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia (AML)", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Core-binding factor (CBF) AML with molecular diagnosis of RUNX1-RUNX1T1 fusion\n             transcript resulting from t(8;21)(q22;q22) (or a variant form) or of CBFB-MYH11\n             fusion transcript resulting from inv(16)(p13.1q22)/t(16;16)(p13.1;q22) as assessed in\n             one of the central AMLSG reference la-boratories (Ulm, Hannover)\n\n          -  Age \u2265 18; there is no upper age limit\n\n          -  No prior chemotherapy for leukemia except hydroxyurea for up to 5 days during the\n             diagnostic screening phase\n\n          -  Non-pregnant and non-nursing. Due to the unknown teratogenic potential of dasatinib\n             in humans, pregnant or nursing patients may not be enrolled. Women of childbearing\n             potential (WOCBP) must have a negative serum or urine pregnancy test within a\n             sensitivity of at least 25 mIU/mL with-in 72 hours prior to registration. Women of\n             child-bearing potential must either commit to contin-ued abstinence from heterosexual\n             intercourse or begin TWO acceptable methods of birth control - one highly effective\n             method (e.g., IUD, hormonal, tubal ligation, or partner's vasectomy), and one\n             additional effective method (e.g., latex condom, diaphragm, or cervical cap) - AT THE\n             SAME TIME, at least four weeks before she begins dasatinib therapy. \"Women of\n             childbearing potential\" is defined as a sexually active mature woman who has not\n             undergone a hysterectomy or who has had menses at any time in the preceding 24\n             consecutive months.\n\n          -  Men must agree not to father a child and must use a latex condom during any sexual\n             contact with women of childbearing potential while taking dasatinib and for 3 months\n             after therapy is stopped, even if they have undergone a successful vasectomy.\n\n          -  Signed written informed consent.\n\n        Exclusion Criteria:\n\n          -  Performance status WHO >2\n\n          -  Pulmonary edema and/or pleural/pericardial effusion within 14 days of day 1. If\n             edema/effusion resolves to CTC Grade \u22641, patients can be treated with dasatinib.\n\n          -  Patients with ejection fraction <50% by echocardiography within 14 days of day 1\n\n          -  Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or AP\n             >2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or\n             restrictive ventilation disorder)\n\n          -  Uncontrolled infection\n\n          -  Patients with a \"currently active\" second malignancy other than non-melanoma skin\n             cancers. Pa-tients are not considered to have a \"currently active\" malignancy, if\n             they have completed therapy and are considered by their physician to be at less than\n             30% risk of relapse within one year.\n\n          -  Severe neurological or psychiatric disorder interfering with ability of giving an\n             informed consent\n\n          -  Known positive for HIV, active HBV, HCV, or Hepatitis A infection\n\n          -  Bleeding disorder independent of leukemia\n\n          -  No consent for registration, storage and processing of the individual disease\n             characteristics and course as well as information of the family physician and/or\n             other physicians involved in the treatment of the patient about study participation.\n\n          -  No consent for biobanking."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "277", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013648", 
            "org_study_id": "AMLSG 21-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Investigational arm", 
                "intervention_name": "Dasatinib", 
                "intervention_type": "Drug", 
                "other_name": "Sprycel"
            }, 
            {
                "arm_group_label": [
                    "Standard arm", 
                    "Investigational arm"
                ], 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug", 
                "other_name": "ARA-cell"
            }, 
            {
                "arm_group_label": [
                    "Standard arm", 
                    "Investigational arm"
                ], 
                "intervention_name": "Daunorubicin", 
                "intervention_type": "Drug", 
                "other_name": "Daunoblastin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Daunorubicin", 
                "Dasatinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "AML", 
            "Dasatinib", 
            "Core Binding Factor (CBF)"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel\u2122) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)", 
        "overall_contact": {
            "email": "hartmut.doehner@uniklinik-ulm.de", 
            "last_name": "Hartmut Doehner, Prof. Dr.", 
            "phone": "0049-731-500-", 
            "phone_ext": "45501"
        }, 
        "overall_contact_backup": {
            "email": "peter.paschka@uniklinik-ulm.de", 
            "last_name": "Peter Paschka, Dr.", 
            "phone": "0049-731-500", 
            "phone_ext": "45746"
        }, 
        "overall_official": {
            "affiliation": "University of Ulm", 
            "last_name": "Hartmut Doehner, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess event-free survival (EFS) after intensive induction (daunorubicin and cytarabine) and consolidation (high-dose cytarabine) chemotherapy with or without dasatinib in patients with CBF-AML", 
            "measure": "Event-free Survival", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013648"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Ulm", 
            "investigator_full_name": "Prof. Dr. Hartmut Doehner", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cumulative incidence of relapse (CIR)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Cumulative incidence of death (CID)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "relapse-free survival", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Pharmacodynamic inhibition of KIT as assessed by the KIT plasma inhibitory assay (PIA)", 
                "measure": "PIA analysis", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Type, frequency, severity (graded using the National Cancer Institute Common Terminology Crite-ria for Adverse Events [NCI CTCAE] version 4.03), timing and relatedness of non-hematologic toxicity observed during different treatment cycles.", 
                "measure": "toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "7 months (standard arm) / 19 months (investigational arm)"
            }
        ], 
        "source": "University of Ulm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Ulm", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}